Dependency of Experimental Autoimmune Encephalomyelitis Induction on MOG^sub 35-55^ Properties Modulating Matrix Metalloproteinase-9 and Interleukin-6

• Published in: Neurochemical research Vol. 41; no. 4; p. 666
• Main Authors: Seo, Ji-eun, Hasan, Mahbub, Han, Joon-seung, Kim, Nak-kyoon, Lee, Ji Eun, Lee, Kang Mi, Park, Ju-hyung, Kim, Ho Jun, Son, Junghyun, Lee, Jaeick, Kwon, Oh-seung
• Format: Journal Article
• Language: English
• Published: New York Springer Nature B.V 01.04.2016
• ISSN: 0364-3190; 1573-6903
• DOI: 10.1007/s11064-015-1732-9

Experimental autoimmune encephalomyelitis (EAE) is commonly induced with myelin oligodendrocyte glycoprotein (MOG)^sub 35-55^; occasionally, EAE is not well induced despite MOG^sub 35-55^ immunization. To confirm that EAE induction varies with difference in MOG^sub 35-55^ properties, we compared three MOG^sub 35-55^ from different commercial sources, which are MOG-A, MOG-B, and MOG-C. The peptides induced EAE disease with 100, 40, and 20 % incidence, respectively. Compared with others, MOG-A showed higher peptide purity (99.2 %) and content (92.2 %) and presented a sheet shape with additional sodium and chloride chemical elements. In MOG-A-treated group, MMP-9 activity and IL-6 levels were considerably higher than the other groups in CNS tissues, and significantly increased VCAM-1, IFN-γ, and decreased IL-4 were also shown compared to MOG-B- and/or MOG-C-treated group. In conclusion, the immunological and toxicological changes by the difference in MOG^sub 35-55^ properties modulate EAE induction, and MOG^sub 35-55^ which affects MMP-9 activity and IL-6 levels may be the most effective EAE-inducing antigen. This study can be potentially applied by researchers using MOG^sub 35-55^ peptide and manufacturers for MOG^sub 35-55^ synthesis.